ONCO Stock Overview

A pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. More details

ONCO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Makes less than USD$1m in revenue (CA$0)

Does not have a meaningful market cap (CA$31M)

Less than 3 years of financial data is available

My Notes

Capture your thoughts, links and company narrative

Onco-Innovations Limited Competitors

Thiogenesis Therapeutics

TSXV:TTI

CA$27.3m

IBEX Technologies

TSXV:IBT

CA$35.3m

Microbix Biosystems

TSX:MBX

CA$50.2m

Cytophage Technologies

TSXV:CYTO

CA$16.5m

Price History & Performance

Summary of share price highs, lows and changes for Onco-Innovations
Historical stock prices
Current Share Price	CA$0.70
52 Week High	CA$0.70
52 Week Low	CA$0.56
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.69%

Recent updates

Shareholder Returns

	ONCO	CA Biotechs	CA Market
7D	9.4%	-3.7%	-2.6%
1Y	n/a	11.5%	15.2%

Return vs Industry: Insufficient data to determine how ONCO performed against the Canadian Biotechs industry.

Return vs Market: Insufficient data to determine how ONCO performed against the Canadian Market.

Price Volatility

Is ONCO's price volatile compared to industry and market?
ONCO volatility
ONCO Average Weekly Movement	n/a
Biotechs Industry Average Movement	13.2%
Market Average Movement	8.1%
10% most volatile stocks in CA Market	17.3%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: ONCO's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: Insufficient data to determine ONCO's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	1	Thomas O’Shaughnessy	oncoinnovations.com

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. Its lead product candidate is ONC010, a novel inhibitor of the deoxyribonucleic acid repair enzyme polynucleotide kinase 3'-phosphatase in a nanoparticle formulation based on the drug delivery technology. The company is headquartered in Calgary, Canada.

Onco-Innovations Limited Fundamentals Summary

How do Onco-Innovations's earnings and revenue compare to its market cap?
ONCO fundamental statistics
Market cap	CA$30.57m
Earnings (TTM)	-CA$64.37k
Revenue (TTM)	n/a

0.0x

P/S Ratio

-474.9x

P/E Ratio

Is ONCO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ONCO income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$64.37k
Earnings	-CA$64.37k

Last Reported Earnings

Apr 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0015
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did ONCO perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/20 17:23
End of Day Share Price	2024/12/20 00:00
Earnings	2024/04/30
Annual Earnings	2024/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Onco-Innovations Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution

Onco-Innovations CNSX:ONCO Stock Report